Score Overview
See the full market ranking โ
Sellas Life Sciences Group Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 1.9K to $ 0.00 and net income went from -$ 16M to -$ 26M. Revenue increased in 0 of those 5 years; net income in 3.
Sellas Life Sciences Group Inc currently holds a 5-year HDB Score of 3.2 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 11.77 | โ |
1 Year2025-08-12 | $ 1.61 | 7x |
5 Years2021-08-12 | $ 9.91 | 18.77% |
10 Years2016-08-12 | $ 12.66K | -99.91% |
All Time2017-12-29 | $ 393.00 | -97.01% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | All Time2017-12-29 |
|---|---|---|---|---|---|
| Price | $ 11.77 | $ 1.61 | $ 9.91 | $ 12.66K | $ 393.00 |
| Return | โ | 7x | 18.77% | -99.91% | -97.01% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 0.00 | -$ 29M | $ 107M |
| 2025 | $ 0.00 | -$ 26M | $ 71M |
| 2024 | $ 0.00 | -$ 30M | $ 13M |
| 2023 | $ 0.00 | -$ 37M | $ 2M |
| 2022 | $ 1M | -$ 41M | $ 17M |
| 2021 | $ 7M | -$ 20M | $ 21M |
| 2020 | $ 1.9K | -$ 16M | $ 35M |
| 2019 | $ 0.00 | -$ 19M | $ 7M |
| 2018 | $ 0.00 | -$ 27M | $ 5M |
| IPO2017 | $ 0.00 | -$ 23M | $ 2M |
Explore beyond SLS
You're looking at Sellas Life Sciences Group Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score โ 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.